{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:04:51Z","timestamp":1791482691706,"version":"4.3.4"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1093\/nutrit\/nux011","type":"journal-article","created":{"date-parts":[[2017,2,27]],"date-time":"2017-02-27T20:18:13Z","timestamp":1488226693000},"page":"471-490","source":"Crossref","is-referenced-by-count":30,"title":["Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation"],"prefix":"10.1093","volume":"75","author":[{"given":"Clara","family":"Minto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"Lamprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,25]]},"reference":[{"key":"key\n\t\t\t\t20170915022422_nux011-B1","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.2903\/j.efsa.2014.3759","article-title":"Scientific opinion on dietary reference values for niacin","volume":"12","author":"European Food Safety Authority","year":"2014","journal-title":"EFSA J"},{"key":"key\n\t\t\t\t20170915022422_nux011-B2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/jnnp.2003.025858","article-title":"Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline","volume":"75","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t20170915022422_nux011-B3","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-0348-6540-1_12","article-title":"The relationship of pellagra to corn and the low availability of niacin in cereals","volume":"44","year":"1983","journal-title":"Experientia Suppl"},{"key":"key\n\t\t\t\t20170915022422_nux011-B4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/MOL.0b013e3282364add","article-title":"Niacin in cardiovascular prevention: mechanisms, efficacy, and safety","volume":"18","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2007.02.004","article-title":"Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence","volume":"1","year":"2007","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B6","first-page":"1711","article-title":"Present-day uses of niacin: effects on lipid and non-lipid parameters","volume":"11","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t20170915022422_nux011-B7","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170915022422_nux011-B8","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1463-1326.2010.01289.x","article-title":"Long-term efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome","volume":"12","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"key\n\t\t\t\t20170915022422_nux011-B9","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1172\/JCI109385","article-title":"Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism","volume":"63","year":"1979","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20170915022422_nux011-B10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jama.1990.03450060069031","article-title":"Nicotinic acid as therapy for dyslipidemia in non\u2013insulin-dependent diabetes mellitus","volume":"264","year":"1990","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170915022422_nux011-B11","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1001\/jama.1938.02790510034009","article-title":"A reaction to the oral administration of nicotinic acid","volume":"111","year":"1938","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170915022422_nux011-B12","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jama.1938.02790330004002","article-title":"The treatment of subclinical and classic pellagra. Use of nicotinic acid, nicotinic acid amide and sodium nicotinate, with special reference to the vasodilator action and the effect on mental symptoms","volume":"111","year":"1938","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170915022422_nux011-B13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0002-8703(40)91029-8","article-title":"A study of the effects of nicotinic acid and related pyridine and pyrazine compounds on the temperature of the skin of human beings","volume":"20","year":"1940","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170915022422_nux011-B14","first-page":"165","article-title":"Neurophysiological effects of capsaicin","volume":"320","year":"1984","journal-title":"Brain Res"},{"key":"key\n\t\t\t\t20170915022422_nux011-B15","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/ATVBAHA.113.303346","article-title":"Nicotinic acid activates the capsaicin receptor TRPV1\u2014a potential mechanism for cutaneous flushing","volume":"34","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B16","volume-title":"Tolerable Upper Intake Levels for Vitamins and Minerals","author":"European Food Safety Authority, Scientific Committee on Food, Scientific Panel on Dietetic Products, Nutrition and Allergies","year":"2006"},{"key":"key\n\t\t\t\t20170915022422_nux011-B17","volume-title":"Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline","author":"US Institute of Medicine, Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline","year":"1998"},{"key":"key\n\t\t\t\t20170915022422_nux011-B18","volume-title":"Safe Upper Levels for Vitamins and Mineral","author":"Expert Group on Vitamins and Minerals","year":"2003"},{"key":"key\n\t\t\t\t20170915022422_nux011-B19","first-page":"7","article-title":"Use of the benchmark dose approach in risk assessment","volume":"15","author":"European Food Safety Authority Scientific Committee","year":"2009","journal-title":"EFSA J"},{"key":"key\n\t\t\t\t20170915022422_nux011-B20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","year":"2015","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3810\/pgm.2011.03.2265","article-title":"Important considerations for treatment with dietary supplement versus prescription niacin products","volume":"123","year":"2011","journal-title":"Postgrad Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B22","first-page":"66","article-title":"Niacin: nicotinic acid, nicotinamide, and inositol hexanicotinate","volume-title":"Vitamin and Mineral Safety","year":"2013","edition":"3rd ed."},{"key":"key\n\t\t\t\t20170915022422_nux011-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","year":"1996","journal-title":"Control Clin Trials"},{"key":"key\n\t\t\t\t20170915022422_nux011-B24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.yrtph.2005.06.012","article-title":"Use of benchmark dose and meta-analysis to determine the most sensitive endpoint for risk assessment for dimethoate","volume":"43","year":"2005","journal-title":"Regul Toxicol Pharmacol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B25","volume-title":"Statistical Method in Biological Assay","year":"1964"},{"key":"key\n\t\t\t\t20170915022422_nux011-B26","volume-title":"Nonlinear Regression","year":"1989"},{"key":"key\n\t\t\t\t20170915022422_nux011-B27","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2134\/jeq1989.00472425001800020009x","article-title":"First-year nutrient availability from injected dairy manure","volume":"18","year":"1989","journal-title":"J Environ Qual"},{"key":"key\n\t\t\t\t20170915022422_nux011-B28","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2015"},{"key":"key\n\t\t\t\t20170915022422_nux011-B29","first-page":"1","article-title":"Bioassay analysis using R","volume":"12","year":"2005","journal-title":"J Statist Software"},{"key":"key\n\t\t\t\t20170915022422_nux011-B30","year":"2012"},{"key":"key\n\t\t\t\t20170915022422_nux011-B31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0002-9149(97)00303-2","article-title":"Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg\/dl in patients with hyperlipidemia and coronary artery disease","volume":"80","year":"1997","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B32","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/ajcn\/88.1.30","article-title":"Postprandial triglyceride responses to aerobic exercise and extended-release niacin","volume":"88","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"key\n\t\t\t\t20170915022422_nux011-B33","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.amjcard.2008.02.092","article-title":"Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)","volume":"101","year":"2008","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B34","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0002-9149(03)00318-7","article-title":"Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels","volume":"91","year":"2003","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0002-9149(94)90005-1","article-title":"Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia","volume":"73","year":"1994","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B36","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","year":"2000","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/clc.4960260304","article-title":"A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin","volume":"26","year":"2003","journal-title":"Clin Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B38","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archinte.164.10.1121","article-title":"Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis","volume":"164","year":"2004","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B39","first-page":"1065","article-title":"Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy","volume":"16","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"key\n\t\t\t\t20170915022422_nux011-B40","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0002-9149(01)02338-4","article-title":"Long-term safety and efficacy of a once-daily niacin\/lovastatin formulation for patients with dyslipidemia","volume":"89","year":"2002","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1532-5415.1992.tb01822.x","article-title":"Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin","volume":"40","year":"1992","journal-title":"J Am Geriatr Soc"},{"key":"key\n\t\t\t\t20170915022422_nux011-B42","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000228585","article-title":"Flushing profile of extended-release niacin\/laropiprant at initiation of therapy in Asian lipid clinic patients","volume":"114","year":"2009","journal-title":"Cardiology"},{"key":"key\n\t\t\t\t20170915022422_nux011-B43","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0272-6386(95)90133-7","article-title":"Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial","volume":"25","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20170915022422_nux011-B44","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","year":"2008","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t20170915022422_nux011-B45","first-page":"305","article-title":"A comparison of cholestyramine and nicotinic acid in the treatment of familial type II hyperlipoproteinaemia","volume":"14","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B46","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-9343(97)00311-2","article-title":"A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia","volume":"104","year":"1998","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B47","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2125.1992.tb04067.x","article-title":"A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia","volume":"33","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B48","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-release\/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study","volume":"94","year":"2004","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B49","first-page":"39","article-title":"Niacin extended-release\/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy","volume":"8","year":"2012","journal-title":"Vasc Health Risk Manag"},{"key":"key\n\t\t\t\t20170915022422_nux011-B50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2147\/vhrm.2006.2.1.87","article-title":"Evaluation of efficacy and safety of fixed dose lovastatin and niacinER combination in Asian Indian dyslipidemic patients: a multicentric study","volume":"2","year":"2006","journal-title":"Vasc Health Risk Manag"},{"key":"key\n\t\t\t\t20170915022422_nux011-B51","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","year":"1998","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B52","first-page":"687","article-title":"Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy","volume":"157","year":"2009","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170915022422_nux011-B53","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B54","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol","volume":"160","year":"2000","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B55","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-125-7-199610010-00001","article-title":"Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and \u201cnormal\u201d cholesterol levels. A randomized, placebo-controlled trial","volume":"125","year":"1996","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B56","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1002\/j.1875-9114.1997.tb03095.x","article-title":"Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic","volume":"17","year":"1997","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t20170915022422_nux011-B57","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170915022422_nux011-B58","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima\u2013media thickness","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.amjcard.2003.10.009","article-title":"Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study)","volume":"93","year":"2004","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B60","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B61","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2013.09.034","article-title":"The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT)","volume":"231","year":"2013","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170915022422_nux011-B62","doi-asserted-by":"crossref","first-page":"354","DOI":"10.5301\/jn.5000011","article-title":"Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients","volume":"25","year":"2012","journal-title":"J Nephrol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B63","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","article-title":"A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients","volume":"3","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B64","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2215\/CJN.01470307","article-title":"Niacin lowers serum phosphate and increases HDL cholesterol in dialysis patients","volume":"2","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B65","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11255-006-0001-x","article-title":"Extended release nicotinic acid\u2014a novel oral agent for phosphate control","volume":"38","year":"2006","journal-title":"Int Urol Nephrol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B66","first-page":"58","article-title":"Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: a double-blind randomized clinical trial","volume":"31","year":"2011","journal-title":"Nefrologia"},{"key":"key\n\t\t\t\t20170915022422_nux011-B67","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1523-1755.2004.00482.x","article-title":"Nicotinamide suppresses hyperphosphatemia in hemodialysis patients","volume":"65","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170915022422_nux011-B68","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.plefa.2009.09.003","article-title":"Test\u2013retest stability of the oral niacin test and electrodermal activity in patients with schizophrenia","volume":"81","year":"2009","journal-title":"Prostaglandins, Leukot, Essent Fatty Acids"},{"key":"key\n\t\t\t\t20170915022422_nux011-B69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.plefa.2006.02.002","article-title":"Niacin skin-flush response and electrodermal activity in patients with schizophrenia and healthy controls","volume":"74","year":"2006","journal-title":"Prostaglandins, Leukot, Essent Fatty Acids"},{"key":"key\n\t\t\t\t20170915022422_nux011-B70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.apmr.2010.06.029","article-title":"Safety, tolerance, and efficacy of extended-release niacin monotherapy for treating dyslipidemia risks in persons with chronic tetraplegia: a randomized multicenter controlled trial","volume":"92","year":"2011","journal-title":"Arch Phys Med Rehabil"},{"key":"key\n\t\t\t\t20170915022422_nux011-B71","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/bjo.2004.046607","article-title":"Effect of niacin on the choroidal circulation of patients with age related macular degeneration","volume":"88","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B72","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.amjcard.2013.06.035","article-title":"Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels","volume":"112","year":"2013","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B73","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0002-9343(99)80185-5","article-title":"The prevalence of side effects with regular and sustained-release nicotinic acid","volume":"99","year":"1995","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170915022422_nux011-B74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/bdd.555","article-title":"The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet","volume":"28","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"key\n\t\t\t\t20170915022422_nux011-B75","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]","volume":"3","year":"2003","journal-title":"BMC Clin Pharmacol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B76","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jacl.2012.11.005","article-title":"Apple pectin for the reduction of niacin-induced flushing","volume":"7","year":"2013","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B77","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy","volume":"99","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacl.2009.02.009","article-title":"Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study","volume":"3","year":"2009","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20170915022422_nux011-B79","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2008.02.026","article-title":"Safety of niacin and simvastatin combination therapy","volume":"101","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["Nutrition Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nutritionreviews\/article-pdf\/75\/6\/471\/19920378\/nux011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T18:36:54Z","timestamp":1719081414000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/nutritionreviews\/article\/75\/6\/471\/3852639\/Definition-of-a-tolerable-upper-intake-level-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,25]]},"references-count":79,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,5,25]]},"published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1093\/nutrit\/nux011","relation":{},"ISSN":["0029-6643","1753-4887"],"issn-type":[{"value":"0029-6643","type":"print"},{"value":"1753-4887","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,25]]}}}